Sagespring Wealth Partners LLC Acquires 9,610 Shares of Pfizer Inc. $PFE

Sagespring Wealth Partners LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 21.7% during the second quarter, HoldingsChannel.com reports. The firm owned 53,990 shares of the biopharmaceutical company’s stock after purchasing an additional 9,610 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in Pfizer were worth $1,309,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after buying an additional 3,943,397 shares in the last quarter. Amundi grew its holdings in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Invesco Ltd. increased its position in shares of Pfizer by 2.8% during the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after acquiring an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG increased its position in shares of Pfizer by 7.0% during the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock valued at $715,581,000 after acquiring an additional 1,846,436 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.8%

Pfizer stock opened at $24.53 on Wednesday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82. The company has a market cap of $139.44 billion, a P/E ratio of 13.05, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a 50-day simple moving average of $24.88 and a two-hundred day simple moving average of $24.12.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley lowered their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday. Finally, UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.